Search Results
Sep 03, 2026, 07:15 ET ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
days.About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).ADC
More news about: ADC Therapeutics SA
Sep 03, 2026, 07:00 ET Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion, and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product). Current international treatment guidelines recommend the use of ARIKAYCE for appropriate patients. ARIKAYCE is a novel, inhaled, once-daily
More news about: Insmed Incorporated
Sep 03, 2026, 07:00 ET Gravie Launches Industry's First Hybrid Benefit Solution as an Answer to Employers Facing Rising Healthcare Costs
small and midsize businesses heading into 2027, as these companies continue to face particular pressure from rising hospital, physician and prescription drug costs. At the same time, employers and benefits brokers are increasingly considering alternatives to traditional fully insured coverage, including both
More news about: Gravie, Inc
Sep 03, 2026, 07:00 ET Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
clinical candidates for Pseudomonas aeruginosa, S. aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing to support full commercialization.Forward
More news about: Armata Pharmaceuticals, Inc.
Sep 03, 2026, 06:40 ET Potassium Fluoride Market worth $0.51 billion by 2032 - Exclusive Report by MarketsandMarkets™
potassium fluoride market has diversified its demand to several applications, including use in chemicals manufacturing, agriculture, pharmaceutical drug manufacturing, glass etching, metal treating, flux used for soldering, and semiconductor production. Potassium Fluoride is an important source of fluoride
More news about: MarketsandMarkets
Sep 03, 2026, 06:11 ET Some Hair Loss in Men Is Linked to Use of Weight Loss Drugs
reason than weight loss, including one-fifth of women ages 50 to 64, according to surveys. Since the first GLP-1 drug (Ozempic) was approved by the Food and Drug Administration in 2020, prescriptions for the medication have more than tripled.Funding support for this study was provided
More news about: NYU Langone Health System
Sep 03, 2026, 06:00 ET Superluminal Medicines Announces Oversubscribed $60 Million Series B Financing to Advance Lead Program in Rare Genetic Forms of Obesity into the Clinic
targets.""The caliber of this financing syndicate speaks to the progress Superluminal has made in establishing a differentiated approach to small molecule drug discovery," said Nandita Shangari, managing director at RA Capital Management and a member of Superluminal's Board of Directors. "Bringing together
More news about: Superluminal Medicines
Sep 03, 2026, 05:37 ET Gan & Lee and Menarini Group Partner to Advance Bofanglutide in Europe
metabolic space, a critical area that affects an increasingly broad patients' population in need.Bofanglutide is a China Class 1 investigational drug independently developed by Gan & Lee. Its key feature is a once-every-two-weeks subcutaneous dosing regimen, which reduces administration frequency
More news about: Menarini Industrie Farmaceutiche Riunite
Sep 03, 2026, 04:03 ET Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
data for Deramiocel. The Company failed to secure the FDA's agreement to this change before it resubmitted a Biologics License Application for the drug. Based on these facts, Capricor's public statements were false and materially misleading throughout the class period.If you are a shareholder
More news about: DJS Law Group LLP
Sep 03, 2026, 01:22 ET EpiVax führt KI-gestützte Modelle zur Vorhersage der Immunogenität ein
ein aktualisiertes JanusMatrix™-Modell, einen verfeinerten, toleranzangepassten Immunogenitäts-Score sowie ein verbessertes Vorhersagemodell für Anti-Drug-Antikörper (ADA) ein, die tiefere Einblicke in das Immunogenitätsrisiko ermöglichen sollen.
More news about: EpiVax, Inc.
Sep 02, 2026, 20:30 ET Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain
index series, including MSCI Global Small Cap Indexes, the China Securities Index (CSI) Series (CSI Hong Kong Connect Innovative Drug Index, CSI Hong Kong Brand Name Drug Index, and CSI HK Connect Health Care Composite Index), Hang Seng Composite Index, Hang Seng Healthcare Index, Hang Seng Biotechnology
More news about: Insilico Medicine
Sep 02, 2026, 20:00 ET 갈리앵 재단, 제1회 2026 프리 갈리앵 코리아 어워드 후보 발표
Makary) 박사의 기조연설로 문을 올리며 학계, 산업계 및 정부의 저명한 연사들과 함께 리제네론(Regeneron)의 창업자 겸 최고경영자 레너드 슐라이퍼(Leonard Schleifer) 박사와의 세션을 진행할 예정이다.국가신약개발재단(Korea Drug Development Fund, KDDF)의 위원장 겸 대표인 박영민 박사는 "한국은 오랫동안 과학적 혁신과 임상적 우수성의 최전선에 서 있었으며, 제1회 프리 갈리앵 코리아는 그러한 리더십에 걸맞은 인정이다. 위원장으로서 이토록 저명한 동료들과 함께 의학의 경계를
More news about: The Galien Foundation
Sep 02, 2026, 17:00 ET Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform,
More news about: Akeso, Inc.
Sep 02, 2026, 16:58 ET Nanochon Performs First Case in the Chondrograft™ First in Human Clinical Study
focal cartilage defects through a minimally invasive regenerative approach. Nanochon has received Breakthrough Device Designation from the U.S. Food and Drug Administration.
More news about: Nanochon
Sep 02, 2026, 16:05 ET Nuvation Bio to Participate in Upcoming Investor Conferences
includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation,
More news about: Nuvation Bio, Inc.
Sep 02, 2026, 16:01 ET Foventa further strengthens management team with key CMO and CFO appointments
Zaiba and Julia bring decades of biotech industry experience to Foventa. Zaiba has worked for over 20 years in clinical ophthalmology and ophthalmic drug development across industry and academia, most recently as Global Medical Director and Therapeutic Area Lead for Ophthalmology at Medpace. She received
More news about: Foventa Therapeutics
Sep 02, 2026, 14:46 ET MemoryDriver Relaunches Sept. 15 With a National "Beat the Clock" Navigation Challenge
diagnose, treat, cure or prevent Alzheimer's disease, dementia or any other medical condition. It has not been cleared or approved by the U.S. Food and Drug Administration.The research described above is observational and was conducted independently of Evon Medics. It informs the design rationale
More news about: EvON Medics
Sep 02, 2026, 13:22 ET Atreon Orthopedics® Adds Darin Johnson to Board of Directors
experience, Johnson served as a Board Director for JointMedica Ltd, supporting the company's commercialization strategy and governance for a U.S. Food and Drug Administration (FDA) Breakthrough Device-designated hip resurfacing technology."I'm honored to join Atreon's Board at such a pivotal moment,"
More news about: Atreon Orthopedics
Sep 02, 2026, 11:16 ET EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction
risk of biotherapeutics. The release introduces an updated JanusMatrix™ model, a refined tolerance-adjusted immunogenicity score, and an enhanced anti-drug antibody (ADA) prediction model designed to provide deeper insight into immunogenicity risk.
More news about: EpiVax, Inc.
Sep 02, 2026, 11:04 ET EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction
risk of biotherapeutics. The release introduces an updated JanusMatrix™ model, a refined tolerance-adjusted immunogenicity score, and an enhanced anti-drug antibody (ADA) prediction model designed to provide deeper insight into immunogenicity risk.
More news about: EpiVax, Inc.
Sep 02, 2026, 11:00 ET ISS National Lab Reaches 1,000-Payload Milestone as CASIS Celebrates 15 Years of Leadership
Sanofi, and others. These companies use the unique space environment to help advance drug discovery, therapeutic formulations, vaccine development, and drug-delivery technologies, accelerating the path to next-generation medicines.Startups and emerging companies:
More news about: International Space Station National Lab
Sep 02, 2026, 11:00 ET Thyme Care Closes $125+ Million Series E, Establishes Thyme Companies to Broaden Its Impact Across the Oncology Ecosystem
adoption of lower-cost biosimilars and improving clinical trial accrual, where slow enrollment limits patient access to beneficial trials and slows drug development. The first of these businesses is expected to launch later this year.To support this next phase of growth, Thyme Care co-founder
More news about: Thyme Care
Sep 02, 2026, 10:31 ET Autoimmune Uveitis Market to Expand at a CAGR of 7% During the Forecast Period (2026-2036) as Novel Treatments Challenge the Existing Therapeutic Landscape | DelveInsight
immunosuppressive agents currently dominate the autoimmune uveitis treatment landscape; however, targeted biologics, JAK/TYK2 inhibitors, and advanced localized drug delivery systems are expected to drive future innovation by providing safer, more durable, and steroid-sparing treatment options.Autoimmune
More news about: DelveInsight Business Research, LLP
Sep 02, 2026, 10:30 ET Biosimilars Market worth $70.79 billion by 2036 - Exclusive Report by MarketsandMarkets™
biosimilar production capacity. Similarly, Biocon Biologics is investing in the expansion of its Malaysia manufacturing facility to double drug-substance and drug-product capacity, supporting its growing portfolio of insulin and other biosimilars. These investments are particularly important for high-value
More news about: MarketsandMarkets
Sep 02, 2026, 10:11 ET AARD Investor Alert: Aardvark Therapeutics, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
Offering materials stated the drug was "approximately 99% restricted to the gut with minimal systemic exposure" and "resulted in no serious adverse events (SAEs)." Management represented that the program had aligned with the FDA on a design believed sufficient to support a new drug application.The
More news about: Levi & Korsinsky, LLP